Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Infinity Pharmaceuticals has reported positive preliminary results from a Phase 1 study of IPI-926, an oral small molecule that targets the Hedgehog pathway.
Subscribe to our email newsletter
IPI-926 has demonstrated the ability of IPI-926 to inhibit the Hedgehog pathway, further supporting the Phase 1b/2 study of IPI-926 in combination with Gemzar (gemcitabine) in patients with previously untreated, metastatic pancreatic cancer, which is enrolling patients, Infinity said.
In the study, IPI-926 was well tolerated and resulted in clinical activity in patients with basal cell carcinoma (BCC).
Antonio Jimeno, the lead investigator of study, said that the study provides important information about the tolerability and anti-tumor activity of IPI-926 in patients with solid tumors and confirms the hypothesis that inhibition of the Hedgehog pathway may be an important new approach to treating the broad range of cancers in which this pathway is implicated.
Infinity Pharma R&D president Julian Adams said that they are encouraged by the clinical data of IPI-926 showing a pharmacokinetic profile that supports once daily dosing as well as activity in patients with basal cell carcinoma.
"Having demonstrated that IPI-926 has on-target activity against the Hedgehog pathway, these results further support our Phase 1b/2 trial in pancreatic cancer. We are currently evaluating additional indications in which to advance IPI-926," Adams said.